Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

<p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p>

Gorde:
Xehetasun bibliografikoak
Egile nagusia: Stephanie Lheureux (16797697) (author)
Beste egile batzuk: Stephenie D. Prokopec (16797700) (author), Leslie E. Oldfield (16797703) (author), Eduardo Gonzalez-Ochoa (16375918) (author), Jeffrey P. Bruce (16797706) (author), Derek Wong (15135437) (author), Arnavaz Danesh (15135449) (author), Dax Torti (15135467) (author), Jonathan Torchia (16797709) (author), Alexander Fortuna (16797712) (author), Sharanjit Singh (16797715) (author), Matthew Irving (16797718) (author), Kayla Marsh (15135470) (author), Bernard Lam (15051558) (author), Vanessa Speers (16797721) (author), Aleksandra Yosifova (16797724) (author), Ana Oaknin (14956029) (author), Ainhoa Madariaga (15129719) (author), Neesha C. Dhani (16797727) (author), Valerie Bowering (16797730) (author), Amit M. Oza (15129737) (author), Trevor J. Pugh (14940894) (author)
Argitaratua: 2025
Gaiak:
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
Deskribapena
Gaia:<p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p>